Ketorolac Mylan

Ketorolac trometamol, the active ingredient in Ketorolac Mylan, is a nonsteroidal anti‑inflammatory drug (NSAID) presented as a sterile injectable solution for intramuscular and intravenous use. It is employed for short‑term management of moderate to severe acute pain, including postoperative pain, in adult patients.

GNH USA supplies Ketorolac Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution.

Ketorolac Mylan is an NSAID indicated for conditions that involve acute pain pathways.

- Post‑operative pain: provides rapid analgesia after surgical procedures - Moderate to severe acute pain: reduces pain intensity when opioid‑sparing therapy is desired - Short‑term pain management (≤5 days): used to control pain where NSAIDs are appropriate

Ketorolac Mylan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Headache - Dizziness or vertigo - Injection‑site pain or erythema - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Gastrointestinal bleeding or perforation - Acute renal impairment or failure - Severe hypersensitivity reactions, including anaphylaxis or Stevens‑Johnson syndrome

When prescribing Ketorolac Mylan, clinicians should observe several safety precautions to minimise risk.

- Renal function: assess baseline renal status and avoid use in patients with severe renal impairment. - Bleeding risk: avoid in individuals with active peptic ulcer disease or concurrent anticoagulant therapy. - Cardiovascular disease: use cautiously in patients with coronary artery disease or uncontrolled hypertension. - Pregnancy: contraindicated in the third trimester and should be avoided during pregnancy unless benefits outweigh risks. - Drug interactions: review concomitant NSAIDs, anticoagulants, and ACE inhibitors before initiating therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Ketorolac Mylan can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin, heparin): additive risk of serious bleeding. - Concurrent NSAIDs or COX‑2 inhibitors: increased gastrointestinal toxicity and renal adverse effects.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may potentiate renal function decline, especially in volume‑depleted patients. - Lithium: ketorolac may raise serum lithium concentrations, necessitating monitoring. - Methotrexate: reduced clearance can lead to toxicity; monitor levels.